# Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects

> **NCT04334460** · PHASE2 · COMPLETED · sponsor: **Blade Therapeutics** · enrollment: 120 (actual)

## Conditions studied

- Sars-CoV-2
- Covid19

## Interventions

- **DRUG:** BLD-2660

## Key facts

- **NCT ID:** NCT04334460
- **Lead sponsor:** Blade Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-04
- **Primary completion:** 2020-11-11
- **Final completion:** 2021-06-21
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04334460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04334460, "Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04334460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*